The Israeli pharmaceutical giant Teva announced today that it had received final approval from the FDA (the U.S. Food and Drug Administration) to produce and market tablets of 2 and 4 mg. of the antispastic medication Tizanidine HCl. This medication is the generic version of Zanaflex tablets. Zanaflex is currently sold for about $100 for 150 4-mg. tablets, and its total annual sales are reported at $178 million.
In light of the skyrocketing cost of pharmaceuticals in the United States, America is increasingly dependent on the generic drugs produced by Petach Tikva- based Teva, its largest supplier of such. . Israel21c.org recently reported that Teva currently produces one in every 15 prescriptions filled in the United States. Drugs produced by the Israeli company include anti-infective, heart, pain and other medications. In 2001, Teva introduced to the market 20 new drugs, and has 61 new product registrations awaiting FDA approval for this year.
In light of the skyrocketing cost of pharmaceuticals in the United States, America is increasingly dependent on the generic drugs produced by Petach Tikva- based Teva, its largest supplier of such. . Israel21c.org recently reported that Teva currently produces one in every 15 prescriptions filled in the United States. Drugs produced by the Israeli company include anti-infective, heart, pain and other medications. In 2001, Teva introduced to the market 20 new drugs, and has 61 new product registrations awaiting FDA approval for this year.